Literature DB >> 23259989

Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.

Julia Hartmann1, Friederike Braulke, Ursula Sinzig, Gerald Wulf, Jens Holger Maas, Frank Konietschke, Detlef Haase.   

Abstract

In patients with myelodysplastic syndromes (MDS) iron overload caused by long-term red blood cell transfusions is an important factor for comorbidity especially in low-risk MDS. In this report we present the results of a comparative study based on colony formation assays of hematopoietic cells in MDS patients with and without iron overload. We demonstrate that iron overload suppresses the proliferation of erythroid progenitors cells (BFU-E), while the myeloid compartment (CFU-GM) was not found to be affected. Even patients with slightly elevated ferritin values show an impaired proliferation capacity in comparison to patients with normal ferritin levels. Furthermore, we show that this negative impact is reversible by sufficient iron chelation therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23259989     DOI: 10.1016/j.leukres.2012.11.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  20 in total

Review 1.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

2.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

3.  Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome.

Authors:  Zhantao Yang; Siobán B Keel; Akiko Shimamura; Li Liu; Aaron T Gerds; Henry Y Li; Brent L Wood; Bart L Scott; Janis L Abkowitz
Journal:  Sci Transl Med       Date:  2016-05-11       Impact factor: 17.956

Review 4.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

Review 5.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

Review 6.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Synthesis of Zr metal-organic frameworks (MOFs) to remove Fe3+ from water.

Authors:  Yufei Yuan; Yoonseob Kim
Journal:  STAR Protoc       Date:  2022-06-17

8.  Long-term eltrombopag for bone marrow failure depletes iron.

Authors:  David J Young; Xing Fan; Emma M Groarke; Bhavisha Patel; Ronan Desmond; Thomas Winkler; Andre Larochelle; Katherine R Calvo; Neal S Young; Cynthia E Dunbar
Journal:  Am J Hematol       Date:  2022-03-26       Impact factor: 13.265

9.  Deposition of Iron in the Bone Marrow of a Murine Model of Hematopoietic Acute Radiation Syndrome.

Authors:  W Bradley Rittase; Jeannie M Muir; John E Slaven; Roxane M Bouten; Michelle A Bylicky; W Louis Wilkins; Regina M Day
Journal:  Exp Hematol       Date:  2020-03-30       Impact factor: 3.084

Review 10.  EnvIRONmental Aspects in Myelodysplastic Syndrome.

Authors:  Verena Petzer; Igor Theurl; Günter Weiss; Dominik Wolf
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.